Y-Intercept (HK)’s Immunovant IMVT Stock Holding History

Y-Intercept (HK)’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-21,002	Closed	-$534K	–	1787
2025 Q4	$534K	Buy	+21,002	New	+$468K	0.01%	1215
2024 Q1	–	Sell	-9,241	Closed	-$389K	–	1553
2023 Q4	$389K	Sell	9,241 -12,819	-58%	-$472K	0.04%	722
2023 Q3	$847K	Buy	+22,060	New	+$499K	0.08%	365

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Y-Intercept (HK)'s IMVT Position: Q1 2026 in Review

Y-Intercept (HK) sold out of Immunovant (IMVT) in Q1 2026, closing a stake of 21,002 shares — an estimated $534K sold.

Y-Intercept (HK) first reported a position in IMVT in Q3 2023 and held it in 3 quarters. The position peaked at $847K in Q3 2023. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

Y-Intercept (HK) reported no remaining Immunovant position as of Q1 2026 after selling out during the quarter.
Y-Intercept (HK) sold 21,002 Immunovant shares in Q1 2026, an estimated $534K.
Y-Intercept (HK) first reported a position in Immunovant in Q3 2023 and held it in 3 quarters.
Y-Intercept (HK)'s Immunovant position peaked at $847K in Q3 2023.
215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Y-Intercept (HK)'s 13F filing for Q1 2026, filed 27 Apr 2026.